Umeå University's logo

umu.sePublications
Change search
CiteExportLink to record
Permanent link

Direct link
Cite
Citation style
  • apa
  • ieee
  • modern-language-association-8th-edition
  • vancouver
  • Other style
More styles
Language
  • de-DE
  • en-GB
  • en-US
  • fi-FI
  • nn-NO
  • nn-NB
  • sv-SE
  • Other locale
More languages
Output format
  • html
  • text
  • asciidoc
  • rtf
Menopausal hormone therapy and risk of sarcoidosis: a population-based nested case–control study in Sweden
Clinical Epidemiology Division, Department of Medicine Solna, Karolinska Institutet, Karolinska University Hospital T2, Stockholm, Sweden.
Respiratory Medicine Division, Department of Medicine Solna, Karolinska Institutet, Stockholm, Sweden; Center for Molecular Medicine, Karolinska Institutet and Karolinska University Hospital, Stockholm, Sweden; Respiratory Medicine, Theme Inflammation and Ageing, Karolinska University Hospital, Stockholm, Sweden.
Umeå University, Faculty of Medicine, Department of Clinical Sciences, Obstetrics and Gynecology.ORCID iD: 0000-0002-4988-1967
Department of Medical Epidemiology and Biostatistics, Karolinska Institutet, Stockholm, Sweden; Section of Biostatistics, Department of Public Health, University of Copenhagen, Copenhagen, Denmark.
Show others and affiliations
2024 (English)In: European Journal of Epidemiology, ISSN 0393-2990, E-ISSN 1573-7284Article in journal (Refereed) Epub ahead of print
Abstract [en]

Sarcoidosis incidence peaks in women between 50 and 60 years old, which coincides with menopause, suggesting that certain sex hormones, mainly estrogen, may play a role in disease development. We investigated whether menopausal hormone therapy (MHT) was associated with sarcoidosis risk in women and whether the risk varied by treatment type. We performed a nested case–control study (2007–2020) including incident sarcoidosis cases from the Swedish National Patient Register (n = 2593) and matched (1:10) to general population controls (n = 20,003) on birth year, county, and living in Sweden at the time of sarcoidosis diagnosis. Dispensations of MHT were obtained from the Swedish Prescribed Drug Register before sarcoidosis diagnosis/matching. Adjusted odds ratios (aOR) of sarcoidosis were estimated using conditional logistic regression. Ever MHT use was associated with a 25% higher risk of sarcoidosis compared with never use (aOR 1.25, 95% CI 1.13–1.38). When MHT type and route of administration were considered together, systemic estrogen was associated with the highest risk of sarcoidosis (aOR 1.51, 95% CI 1.23–1.85), followed by local estrogen (aOR 1.25, 95% CI 1.11–1.42), while systemic estrogen-progestogen combined was associated with the lowest risk compared to never users (aOR 1.12, 95% CI 0.96–1.31). The aOR of sarcoidosis did not differ greatly by duration of MHT use. Our findings suggest that a history of MHT use is associated with increased risk of sarcoidosis, with women receiving estrogen administered systemically having the highest risk.

Place, publisher, year, edition, pages
Springer Nature, 2024.
Keywords [en]
Case–control studies, Estrogen, Menopausal hormone therapy, Risk factors, Sarcoidosis, Women
National Category
Cancer and Oncology
Identifiers
URN: urn:nbn:se:umu:diva-219819DOI: 10.1007/s10654-023-01084-3ISI: 001140264300001PubMedID: 38212490Scopus ID: 2-s2.0-85182203174OAI: oai:DiVA.org:umu-219819DiVA, id: diva2:1830172
Funder
Swedish Heart Lung Foundation, 2020-0452Swedish Heart Lung Foundation, 2020-0163Swedish Heart Lung Foundation, o. 2019-0478Swedish Research Council, 2019-01034Swedish Research Council, 2017-01548Swedish Research Council, 2019 -00227Konung Gustaf V:s och Drottning Victorias FrimurarestiftelseAvailable from: 2024-01-22 Created: 2024-01-22 Last updated: 2024-01-22

Open Access in DiVA

fulltext(730 kB)41 downloads
File information
File name FULLTEXT01.pdfFile size 730 kBChecksum SHA-512
f53a688edbc196282f2958eb14bcf5f3feaeda854ce108a4ca834333773e85038606cb92f5a8e81bc43b6c81a98e91f34bd9e6a293aee529615f4f2c4f70bb4e
Type fulltextMimetype application/pdf

Other links

Publisher's full textPubMedScopus

Authority records

Bixo, Marie

Search in DiVA

By author/editor
Bixo, Marie
By organisation
Obstetrics and Gynecology
In the same journal
European Journal of Epidemiology
Cancer and Oncology

Search outside of DiVA

GoogleGoogle Scholar
Total: 41 downloads
The number of downloads is the sum of all downloads of full texts. It may include eg previous versions that are now no longer available

doi
pubmed
urn-nbn

Altmetric score

doi
pubmed
urn-nbn
Total: 227 hits
CiteExportLink to record
Permanent link

Direct link
Cite
Citation style
  • apa
  • ieee
  • modern-language-association-8th-edition
  • vancouver
  • Other style
More styles
Language
  • de-DE
  • en-GB
  • en-US
  • fi-FI
  • nn-NO
  • nn-NB
  • sv-SE
  • Other locale
More languages
Output format
  • html
  • text
  • asciidoc
  • rtf